Sanofi and Translate Bio have started a first clinical trial of an mRNA-based seasonal flu vaccine, adding to the COVID-19 shot already in testing as part of their three-year old collaboration.

Sanofi is licensing the technology for the combination COVID-flu vaccine, which is separate from the one currently in Novavax's pipeline. In addition to that $1.2 billion, Sanofi is committing up ...

At Sanofi Pasteur, we believe in a world in which no one suffers or dies from a vaccine-preventable disease. As the world’s leading manufacturer of influenza vaccines, we know influenza is still ...

Novavax has previously said that it is expecting phase 3 results for a COVID/flu vaccine in the second half of this year, with a launch slated for 2026, and the agreement with Sanofi points to the ...

The US Food and Drug Administration has granted Fast Track designation to two Sanofi combination vaccine candidates to prevent influenza and COVID-19 infections in individuals 50 years of age and ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

And influenza can extract a enormous toll ... Working alongside French pharma giant Sanofi, Berg is using artificial intelligence and machine learning to better understand the flu and, hopefully ...

Sanofi’s Q3 revenue grew by 12.3% to €13.438 billion, driven by products like Dupixent and influenza vaccines. Dupixent remains a top growth driver, with potential peak sales exceeding $20 ...

“We’re all-in on the U.S.” As for Sanofi, the company commercializes a range of vaccines against influenza, polio, pertussis, Haemophilus influenzae type b-related illness, meningitis and ...

Sanofi’s vaccines business is interested ... acne and broadly protective influenza; pediatric combination vaccines; largescale cell culture-based virus production; vaccine production; and ...

Margaret Haugh (MediCom Consult) provided translation and editing services, which was funded by Sanofi Pasteur MSD. Box 1. Current nomenclature for influenza viruses (WHO 1980). The formal ...